Hyperglycemia

Hyperglycemia is associated with the presence of multiple cardiac antibody types among people with type 1 diabetes, suggesting a novel mechanism for increased cardiovascular risk specific to the disease, according to a speaker.

Obesity and elevated BMI are “the common soil” that grow adverse outcomes related to COVID-19, and clinicians must work with patients to appropriately control risk factors for severe disease, according to a speaker.

A fasting plasma blood glucose measurement at hospital admission was an independent predictor of 28-day mortality and in-hospital complications among people with COVID-19 but without diabetes, study data from Wuhan show.

ED visits for heart attacks, strokes and hyperglycemic crises all dropped in the 10 weeks after the COVID-19 pandemic was declared a national emergency in the United States, CDC data show.

A subset of patients with cancer who received an immune checkpoint inhibitor developed new hyperglycemia, suggesting the therapy may play a role in immune-related insulin resistance.

Adults with diabetes or uncontrolled hyperglycemia hospitalized with COVID-19 experienced a longer length of stay and markedly higher mortality compared with adults without diabetes or uncontrolled hyperglycemia, according to findings published in the Journal of Diabetes Science and Technology.

More than 100,000 children and adults with type 1 diabetes using a hybrid closed-loop insulin delivery system maintained a blood glucose level in the recommended range 71.3% of the time and experienced an improvement in time in range when using the device in automode, according to a real-world analysis accepted for presentation at the Endocrine Society Annual Meeting.

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a phase 2a study published in The Lancet Diabetes & Endocrinology.

Continuous glucose monitors have revolutionized diabetes care since the first such device was approved by the FDA for personal use in 2005. Today, improvements in glucose sensor accuracy, smaller sensor size and ease of use have made it easier than ever for people with diabetes to monitor their blood glucose trends in real time — and Silicon Valley is taking notice.

A follow-on therapy to insulin aspart was shown to be safe and effective for pump use among adults with type 1 diabetes, with no increased incidence of unexplained hypoglycemia when compared with the reference product, according to findings from an open-label crossover study published in Diabetes Technology & Therapeutics.